16 completed, 2 unknown, 1 recruiting, 1 suspended. 21 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 21 | Completed 16, Unknown 2, Recruiting 1, Suspended 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 3, Suspended 1 |
Follow Levodopa: new trials by email Literature Review of Levodopa trials Research Report on Levodopa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease LECIG (levodopa, carbidopa, entacapone intestinal gel), Best oral medication - PARKINSON DISEASE (Disorder) | Phase 3 | Recruiting | University Hospital Tuebingen | 150 | 2025-10-27 | 2026-07-13 |
| A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations HRG2010; Sustained-release Carbidopa/Levodopa administered placebo, Sustained-release Carbidopa/Levodopa; HRG2010 placebo - Parkinson's Disease | Phase 3 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 165 | 2024-11-06 | 2026-06-08 |
| Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease ABBV-951, Placebo for Levodopa/Carbidopa (LD/CD), Levodopa/Carbidopa (LD/CD) - Parkinson's Disease (PD) | Phase 3 | Completed | AbbVie | 174 | 2020-10-19 | 2022-11-18 |
| Effects of 5HTP and LDOPA on CNS Excitability After SCI 5HTP, L-DOPA, Placebo oral tablet - Spinal Cord Injuries | Phase 2 / Phase 3 | Suspended | Jessica M D'Amico | 30 | 2019-06-19 | 2022-10-17 |
| Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease PR Oxycodone, Levodopa, Oxycodone Placebo - Parkinson Disease | Phase 2 / Phase 3 | Completed | University Hospital, Toulouse | 67 | 2016-09-01 | 2026-05-04 |
| A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations ND0612, Placebo - Parkinson's Disease | Phase 3 | Withdrawn | NeuroDerm Ltd. | 2016-08-01 | 2019-12-10 | |
| A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004 Accordion Pill™ Carbidopa/Levodopa - Parkinson's Disease | Phase 3 | Unknown | Intec Pharma Ltd. | 460 | 2016-07-01 | 2018-08-14 |
| A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients Accordion Pill™ Carbidopa/Levodopa, Sinemet®, Placebo -AP-CD/LD - Parkinson's Disease | Phase 3 | Unknown | Intec Pharma Ltd. | 420 | 2016-03-01 | 2019-08-08 |
| Combinational Rehabilitative Therapy and Functional Brain Imaging for Patients Recovering From Motor Stroke Levodopa, Virtual Reality based therapy - Ischaemic Stroke | Phase 3 | Completed | Singapore General Hospital | 9 | 2014-01-01 | 2017-02-10 |
| Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients Rotigotine, Placebo Patch, L-dopa - Idiopathic Parkinson's Disease | Phase 3 | Completed | UCB Pharma | 346 | 2012-07-01 | 2018-04-04 |
| Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease duloxetine, placebo of duloxetine, injection of apomorphine - Parkinson's Disease | Phase 3 | Completed | University Hospital, Toulouse | 28 | 2011-05-01 | 2017-02-23 |
| Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off Tozadenant (SYN115) 60 mg BID, Placebo, Levodopa (L-dopa) - Parkinson's Disease | Phase 2 / Phase 3 | Completed | Biotie Therapies Inc. | 420 | 2011-03-01 | 2019-01-17 |
| Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon BIA 9-1067, Entacapone, Placebo - Parkinson's Disease | Phase 3 | Completed | Bial - Portela C S.A. | 600 | 2011-03-01 | 2015-09-18 |
| Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients. BIA 9-1067, Placebo, Levodopa - Parkinson's Disease | Phase 3 | Completed | Bial - Portela C S.A. | 427 | 2011-03-01 | 2015-10-19 |
| A Trial of Levodopa in Angelman Syndrome Levodopa, Placebo Oral Capsule - Angelman Syndrome | Phase 2 / Phase 3 | Completed | Wen-Hann Tan | 67 | 2011-01-01 | 2020-07-15 |
| SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations Levodopa (Pardoprunox), Placebo Comparator - Advanced Stage Parkinson's Disease | Phase 3 | Completed | Solvay Pharmaceuticals | 295 | 2007-03-01 | 2015-02-27 |
| A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg) - Parkinson's Disease | Phase 3 | Completed | Novartis | 493 | 2005-08-01 | 2017-05-17 |
| Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa - Parkinson's Disease | Phase 3 | Completed | Novartis Pharmaceuticals | 747 | 2004-09-01 | 2012-04-23 |
| Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome pramipexole, levodopa in combination with benserazide - Restless Legs Syndrome | Phase 3 | Completed | Boehringer Ingelheim | 58 | 2003-02-01 | 2013-11-01 |
| A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS cabergoline, levodopa - Restless Legs Syndrome | Phase 3 | Completed | Pfizer | 361 | 2003-01-01 | 2008-10-29 |
Showing 20 of 21. Sign in to see all of them.
Parkinson Disease (16) · Dyskinesias (2) · Restless Legs Syndrome (2) · Angelman Syndrome (1) · Disruptive, Impulse Control, and Conduct Disorders (1) · Ischemic Stroke (1) · Spinal Cord Injuries (1) · Stroke (1) · Tremor (1)
Bial - Portela C S.A. (2) · Intec Pharma Ltd. (2) · University Hospital, Toulouse (2) · AbbVie (1) · Biotie Therapies Inc. (1) · Boehringer Ingelheim (1) · Jessica M D'Amico (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · NeuroDerm Ltd. (1) · Novartis (1) · Novartis Pharmaceuticals (1) · Pfizer (1) · Singapore General Hospital (1) · Solvay Pharmaceuticals (1)
United States (10) · Germany (5) · Canada (4) · Israel (4) · Italy (4) · Ukraine (4) · Bulgaria (3) · France (3) · Poland (3) · Portugal (3) · Spain (3) · Switzerland (3) · United Kingdom (3) · Argentina (2) · Austria (2)
Ann Neale, RN (1) · Anne Slavotinek, MD (1) · Carlos A. Bacino, MD (1) · Cary Fu, MD (1) · Christine Brefel-Courbon, MD (1) · Jessica D'Amico, PhD (1) · Joaquim Ferreira, MD, PhD (1) · Logan Wink, M.D (1) · Lynne M. Bird, MD (1) · Peter A LeWitt, MD (1)
PMID 19058133, PMID 20582993, PMID 21060282, PMID 22101745, PMID 22316635, PMID 25008546, PMID 26725544, PMID 28027332, PMID 28827011, PMID 31127735, PMID 35148289, PMID 36402160, PMID 38850081, PMID 40979212, PMID 41045349, PMID 41324738
2019 (1), 2025 (1)